InterCure Ltd. (INCR) vs SCYNEXIS, Inc. (SCYX)

InterCure Ltd. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. InterCure Ltd. is the larger, with a market value of $55.1M against $38.9M — 1.4× the size. SCYNEXIS, Inc. has negative trailing earnings, so its P/E is not meaningful; InterCure Ltd. trades at 8.8×. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against 16.2%. InterCure Ltd. has the higher net margin (4.88% vs −49.7%) and the higher return on invested capital (0.00% vs −110.7%). Across the 18 metrics below, InterCure Ltd. leads on 12 and SCYNEXIS, Inc. on 6.

Valuation

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
P/E 8.80 n/m 19.25
P/S 0.33 2.11 2.11
P/B 0.33 0.65 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA 7.24 n/m 12.58
EV/Sales 0.66 0.73 2.73
Earnings yield 11.36% (56.95%) (4.38%)
Free cash flow yield (2.02%) (30.71%) 0.00%

Profitability

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Gross margin 32.74% 100.00% 53.94%
Operating margin 0.00% (109.90%) 0.00%
Net margin 4.88% (49.74%) 0.00%
Free cash flow margin 0.00% (64.67%) 0.00%
Return on equity 0.00% (18.38%) (0.40%)
Return on assets 0.00% (15.09%) (3.32%)
Return on invested capital 0.00% (110.72%) 0.00%

Growth

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 16.15% 682.47% 10.01%
EPS growth (last fiscal year) 52.50% 61.36% 49.06%
Revenue growth, 5-year CAGR 31.11% 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.27 0.00 0.05
Current ratio 1.85 9.65 2.31
Net debt to EBITDA (4.07) 2.54 0.97

Dividend

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric INCR SCYX Drug Manufacturers Specialty & Generic median
Market cap 55.10m 38.90m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack